Personal information

Other IDs

Loop profile: 262503

Activities

Collapse all

Employment (1)

Albert Einstein College of Medicine: The Bronx, New York, US

2014-05-01 to present | Associate Professor (Medicine, Cell Biology)
Employment
Source: Self-asserted source
Kira Gritsman

Education and qualifications (3)

Dana Farber Cancer Institute: Boston, MA, US

2004 to 2008 | Clinical Fellow (Hematology/Oncology)
Qualification
Source: Self-asserted source
Kira Gritsman

Columbia University: New York, NY, US

2001 to 2004 | Internal Medicine Resident (Medicine)
Qualification
Source: Self-asserted source
Kira Gritsman

New York University School of Medicine: New York, NY, US

1994 to 2001 | MD, PhD (Cell Biology)
Education
Source: Self-asserted source
Kira Gritsman

Professional activities (2)

American Society of Hematology: Washington, DC, US

Member
Membership
Source: Self-asserted source
Kira Gritsman

American Association for Cancer Research: Philadelphia, PA, US

Member
Membership
Source: Self-asserted source
Kira Gritsman

Funding (3)

Crosstalk Between the cGAS/STING and PI3K/AKT/MTOR Pathways in the Initiation of Myelodysplastic Syndrome

2025-01-01 to 2025-12-31 | Grant
American Cancer Society (Atlanta, US)
GRANT_NUMBER:

TLC-24-1345877-01-TLC
Source: check_circle
ProposalCentral

RON Kinase as a Therapeutic Target in Myeloproliferative Neoplasms

2020-01-01 to 2024-03-31 | Grant
American Cancer Society (Atlanta, US)
DOI: 10.53354/ACS.RSG-19-130-01-DDC.pc.gr.89927
GRANT_NUMBER:

RSG-19-130-01-DDC
Source: check_circle
American Cancer Society - ProposalCentral

PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid Leukemia

2016-04-01 to 2021-03-31 | Grant
National Cancer Institute (Rockville, US)
URL: https://app.dimensions.ai/details/grant/grant.5053958
GRANT_NUMBER: R01CA196973
Source: Self-asserted source
Kira Gritsman via DimensionsWizard

Works (15)

PI3 kinase alpha and delta promote hematopoietic stem cell activation.

JCI insight
2019-05-23 | Journal article
DOI: 10.1172/jci.insight.125832
PMID: 31120863
Source: Self-asserted source
Kira Gritsman

North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.

Blood
2018-08-13 | Journal article
DOI: 10.1182/blood-2018-01-824607
PMID: 30104217
Source: Self-asserted source
Kira Gritsman

IL1RAP potentiates multiple oncogenic signaling pathways in AML.

The Journal of experimental medicine
2018-05-17 | Journal article
DOI: 10.1084/jem.20180147
PMID: 29773641
PMC: PMC5987926
Source: Self-asserted source
Kira Gritsman

Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells.

Frontiers in Oncology
2017-11-13 | Journal article
DOI: 10.3389/fonc.2017.00265
PMID: 29181334
PMC: PMC5693908
Source: Self-asserted source
Kira Gritsman

Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia.

Blood advances
2017-10-26 | Journal article
DOI: 10.1182/bloodadvances.2017007013
PMID: 29296859
PMC: PMC5737118
Source: Self-asserted source
Kira Gritsman

A myeloid tumor suppressor role for NOL3.

The Journal of experimental medicine
2017-02-23 | Journal article
DOI: 10.1084/jem.20162089
PMID: 28232469
PMC: PMC5339683
Source: Self-asserted source
Kira Gritsman

Control of the innate immune response by the mevalonate pathway.

Nature immunology
2016-06-06 | Journal article
DOI: 10.1038/ni.3487
PMID: 27270400
PMC: PMC4955724
Source: Self-asserted source
Kira Gritsman

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.

Leukemia
2016-04-29 | Journal article
DOI: 10.1038/leu.2016.74
PMID: 27125205
Source: Self-asserted source
Kira Gritsman

A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis.

Nature communications
2015-10-07 | Journal article
DOI: 10.1038/ncomms9501
PMID: 26442967
PMC: PMC4598950
Source: Self-asserted source
Kira Gritsman

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Cancer discovery
2015-09-14 | Journal article
DOI: 10.1158/2159-8290.CD-14-0971
PMID: 26370156
PMC: PMC4670806
Source: Self-asserted source
Kira Gritsman

PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Blood
2015-07-13 | Journal article
DOI: 10.1182/blood-2014-12-618801
PMID: 26170031
PMC: PMC4551362
Source: Self-asserted source
Kira Gritsman

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.

Nature medicine
2014-12-08 | Journal article
DOI: 10.1038/nm.3751
PMID: 25485910
PMC: PMC4289115
Source: Self-asserted source
Kira Gritsman

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.

The Journal of clinical investigation
2014-02-24 | Journal article
DOI: 10.1172/JCI69927
PMID: 24569456
PMC: PMC3973083
Source: Self-asserted source
Kira Gritsman

Akt: a double-edged sword for hematopoietic stem cells.

Cell cycle (Georgetown, Tex.)
2010-04-01 | Journal article
DOI: 10.4161/cc.9.7.11362
PMID: 20234178
Source: Self-asserted source
Kira Gritsman

Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.

Blood
2009-12-14 | Journal article
DOI: 10.1182/blood-2009-06-229443
PMID: 20008787
PMC: PMC2826762
Source: Self-asserted source
Kira Gritsman

Peer review (9 reviews for 4 publications/grants)

Review activity for Cell death and differentiation. (1)
Review activity for Cell. (1)
Review activity for Leukemia (5)
Review activity for The Innovation. (2)
How many people are using ORCID?